A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)
11th April 2018 - ongoing
Team: Professor Guruprasad Aithal.
|Professor Guruprasad Aithal||Biography Professor Guruprasad P. Aithal is the Professor of Hepatology and the Head of the Division for the Nottingham Digestive Diseases Centre and Deputy Director of Nottingham Molecular Pathology Node. Professor Aithal is the GI & Liver Disorder…|